Retraining and Control Therapy (ReACT)- Adults
NCT Number: NCT06570954
Acronym: ReACT
Status: NOT_YET_RECRUITING
Study Type: INTERVENTIONAL
Phases: NA
Conditions: Convulsion, Non-Epileptic
Interventions: BEHAVIORAL: ReACT
Sponsor: University of Alabama at Birmingham
Collaborators: National Institute of Mental Health (NIMH)
Sex: ALL
Age: ADULT, OLDER_ADULT
Enrollment: 50
Study Design: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2024-11-01
Completion Date: 2027-12-31
Locations: University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States

Summary:
The purpose of this study is to assess sense of control and catastrophic symptom expectations as targets for Retraining and Control Therapy (ReACT- an intervention focused on changing behaviors and thoughts) for treatment of adult psychogenic non-epileptic seizures (PNES, episodes resembling epileptic seizures but with no correlated epileptiform activity). 19 years and older participants diagnosed with PNES who are treated at UAB FND clinic will engage in twelve sessions of ReACT. Participants will be randomly assigned to one of three conditions: no wait, 3-month waiting period, 6-month waiting period. Sense of control over actions will be measured by the magic and turbulence task, a well-validated measure of sense of control. Participants will complete the cold pressor test (CPT) in which participants hold their hand in cool water for as long as possible up to 3 minutes. Catastrophic symptom expectations in response to the CPT will be measured by Pain Catastrophizing Scale (PCS), pain tolerance (time with hand in water) and cortisol response. Target assessments occur 7 days before treatment and 7 days after the 12th treatment session. Participants randomized to the 3-month and 6-month waiting period will also complete these measures one additional time immediately before the beginning of their waiting period. Long term follow-up assessments will occur at 2 months, 6 months and 12 months after the 12th treatment session. PNES frequency will be measured from 30 days before to 12 months after treatment. Participants randomized to the 3-month or 6-month waiting period conditions will log weekly PNES episodes until the start of therapy.

Primary Outcome Measures: Magic and turbulence task, Measure of perceived sense of control in response to tasks in which control is manipulated; Greater negative numbers indicate improved understanding of control. Assessed at baseline visit, and 1 week and 2 months after the final therapy sessions., 6-12 months|Pain catastrophizing scale- situation specific, Measures catastrophic symptom expectations; score ranges from 0-52, higher scores indicate greater levels of pain-related anxiety. Assessment done after performing Cold Pressor Test. Assessed at baseline visit, and 1 week and 2 months after the final therapy sessions., 6-12 months|Pain tolerance (time), Measures catastrophic symptom expectations. Measured by the total time the participant can keep their hand in cool water during the Cold Pressor Test. Shorter time indicates less pain tolerance. Assessed at baseline visit, and 1 week and 2 months after the final therapy sessions., 6-12 months|Salivary Cortisol, Measures catastrophic symptom expectations. Measured before and after the cold pressor test. Increased cortisol response indicate increased perceived pain severity. Assessed at baseline visit, and 1 week and 2 months after the final therapy sessions., 6-12 months|Pain Rating Scale, Measures perceived pain severity after the CPT; score ranges from 0-100. Higher scores indicate greater perceived pain severity. Assessed at baseline visit, and 1 week and 2 months after the final therapy sessions., 6-12 months|Stroop task, Measure of cognitive inhibition and selective attention, higher scores means poorer cognitive inhibition and selective attention. Assessed at baseline visit, and 1 week and 2 months after the final therapy sessions., 6-12 months
Secondary Outcome Measures: PNES Frequency, Measured by Psychogenic Non-epileptic Seizures (PNES) diary, including frequency, premonitory symptoms, description of PNES symptoms and duration. Assessed 30 days before baseline visit to 12 months after the 12th treatment session., 16-22 months|Pain Catastrophizing Scale (PCS)- General, Measures catastrophic symptom expectations; score ranges from 0-52, higher scores indicate greater levels of pain-related anxiety. Assessment done before performing Cold Pressor Test. Assessed at baseline visit, and 1 week and 2 months after the final therapy sessions., 6-12 months|Anxiety Sensitivity Index (ASI), Assesses catastrophic symptom expectations; scores ranges from 0-64, higher scores indicate greater anxiety. Completed by participant. Assessed at baseline visit, and 1 week, 2 months, 6 months and 12 months after the final therapy sessions., 16-22 months|Shipley, Assesses verbal IQ; higher scores indicate greater verbal IQ. Completed by participant. Assessed at baseline visit., At Baseline|Quality of Life in Epilepsy (QOLIE-31), Assesses health-related quality of life for patients with epilepsy (used in PNES participants by instructing them to consider their PNES when asked about "seizures"); score ranges from 0-100, higher scores indicate better functioning and well-being. Completed by participant. Assessed at baseline visit, and 1 week, 2 months, 6 months and 12 months after the final therapy sessions, 16-22 months|Sense of Agency Question, Single question which asks "How much control do you believe you have over your PNES?", scored using a 4-point Likert scale. Lower score indicates better control over PNES. Completed by participant. Assessed at baseline visit, and 1 week, 2 months, 6 months and 12 months after the final therapy sessions., 16-22 months|LEVEL 2-Somatic Symptom report adapted from the Participant Health Questionnaire, Measures symptom severity; scores ranges from 0-26, higher scores indicate greater symptom severity. Completed by participant. Assessed at baseline visit, and 1 week, 2 months, 6 months and 12 months after the final therapy sessions., 16-22 months|WHO Disability Assessment Schedule (WHODAS2.0), Completed by participant to measure physical functioning and disability in patients with chronic pain; score ranges from 0-100, higher scores indicate greater perceived functional disability. Assessed at baseline visit, and 1 week, 2 months, 6 months and 12 months after the final therapy sessions, 16-22 months|The Impact on Family Scale, Assesses participant's perceptions of the impact of their medical condition on the family; higher scores indicate greater financial burden on the family. Assessed at baseline visit, and 1 week, 2 months, 6 months and 12 months after the final therapy sessions., 16-22 months|Childhood Trauma Questionnaire, History of physical, sexual and/or emotional abuse and physical and emotional neglect. All clinical subscales have a score range of 5-25, higher scores indicate greater abuse/neglect. Completed by participant. Assessed at baseline visit., At baseline|Hospital Anxiety and Depression Scale (HADS), Measures anxiety and depression symptoms in patients; scores ranges from 0-21 for subscales, higher scores indicate increased symptom severity. Completed by participant. Assessed at baseline visit, and 1 week, 2 months, 6 months and 12 months after the final therapy sessions., 16-22 months|The Columbia Suicide Severity Rating Scale (C-SSRS), Measure that addresses the full range of suicidal thoughts and behaviors that suggest a person is at heightened risk of committing suicide; score ranges from 0-25, higher score indicates greater suicidal ideation intensity. Completed by trained research study coordinator.Assessed at baseline visit, and 1 week, 2 months, 6 months and 12 months after the final therapy sessions., 16-22 months|Healthcare Related Stigma Questionnaire, Measures stigma in patients related to their interaction with health care; scores ranges from 0-64, higher scores indicate greater stigma. Completed by participant. Assessed at baseline visit., At baseline|Flanker Inhibitory Control and Attention Subtest, Subtest of the National Institute of Health Toolbox Cognition Battery. Measures executive function and attention; higher scores indicate better performance. Completed by participant. Assessed at 1st therapy session, and 1 week and 2 months after 12th therapy session., 6-12 months|List Sorting Working Memory Subtest, Subtest of the National Institute of Health Toolbox Cognition Battery. Measures working memory; higher scores indicate better performance. Completed by participant. Assessed at 1st therapy session, and 1 week and 2 months after 12th therapy session., 6-12 months|Pattern Comparison Processing Speed Subtest, Subtest of the National Institute of Health Toolbox Cognition Battery. Measures processing speed; higher scores indicate better performance. Completed by participant. Assessed at 1st therapy session, and 1 week and 2 months after 12th therapy session., 6-12 months|Dimensional Change Card Sort Subtest, Subtest of the National Institute of Health Toolbox Cognition Battery. Measures executive function; higher scores indicate better performance. Completed by participant. Assessed at 1st therapy session, and 1 week and 2 months after 12th therapy session., 6-12 months|Picture Sequence Memory Subtest, Subtest of the National Institute of Health Toolbox Cognition Battery. Measures episodic memory; higher scores indicate better performance. Completed by participant. Assessed at 1st therapy session, and 1 week and 2 months after 12th therapy session., 6-12 months|Sleep Duration, Measures total sleep duration in a 24-hour day. Objectively measured using Respironics Actiwatch Spectrum Pro and subjectively measured using sleep diaries. Worn/completed by participant. Assessed for 1 week between baseline visit and 1st therapy session and 1 week between 12th therapy session and 1 week follow-up visit after treatment., 4-10 months|Sleep Efficiency, Measures quality of sleep. Objectively measured using Respironics Actiwatch Spectrum Pro and subjectively measured using sleep diaries. Worn/completed by participant. Assessed for 1 week between baseline visit and 1st therapy session and 1 week between 12th therapy session and 1 week follow-up visit after treatment., 4-10 months|Sleep Onset Latency, Refers to the time it took the child to fall asleep after lying down in bed. Objectively measured using Respironics Actiwatch Spectrum Pro and subjectively measured using sleep diaries. Worn/completed by participant. Assessed for 1 week between baseline visit and 1st therapy session and 1 week between 12th therapy session and 1 week follow-up visit after treatment., 4-10 months|Sleep - Bed Time, Measures total time in bed in a 24-hour day. Objectively measured using Respironics Actiwatch Spectrum Pro and subjectively measured using sleep diaries. Worn/completed by participant. Assessed for 1 week between baseline visit and 1st therapy session and 1 week between 12th therapy session and 1 week follow-up visit after treatment., 4-10 months|Sleep - Wake Time, Measures total awake time in a 24-hour day. Objectively measured using Respironics Actiwatch Spectrum Pro and subjectively measured using sleep diaries. Worn/completed by participant. Assessed for 1 week between baseline visit and 1st therapy session and 1 week between 12th therapy session and 1 week follow-up visit after treatment., 4-10 months|PNES Episode Duration, Measures the duration of a PNES episode. Objectively measured using Respironics Actiwatch Spectrum Pro. Worn by participant. Assessed for 1 week between baseline visit and 1st therapy session and 1 week between 12th therapy session and 1 week follow-up visit after treatment., 4-10 months|Rosenberg Self-esteem scale, This is a 10-item scale measuring self esteem. Score ranges from 0-30 with low scores indicating low self-esteem. Completed by participant at baseline visit and follow-up visits., 16-22 months|Beaver's Self-Report Family Inventory, This is a 36 item scale which assesses a family member's view of overall family competence. Completed by participant at baseline visit., At Baseline|FND Locus of Control: Multidimensional Health Locus of Control (MHLC) Scales, Measures an individual's belief in his/her ability to control health outcomes. Form C of MHLC scale will be completed by participant. Assessed at baseline visit and follow-up visits., 16-22 months|Dysfunctional Attitude Scale (DAS-9), Participant will complete this 9-item self-report measure that aims to determine stable negative attitudes that people with depression hold about themselves, the world, and their future. Assessed at baseline visit and follow-up visits., 16-22 months|Mishel Uncertainty in Illness Questionnaire-Community Form (MUIS-C), Participant will complete this 23-item scale which measures uncertainty about their diagnosis. Assessed at baseline visit and follow-up visits., 16-22 months|Revised Helping Alliance Questionnaire- II, Revised Helping Alliance Questionnaire-II is a 19-item scale will assess the therapist and participants' perception of the therapeutic alliance at follow-ups. Scores ranges from 19-114 with a higher score indicating better therapeutic alliance. Completed at baseline and follow-up visits., 16-22 months|The Credibility/Expectancy Questionnaire, The Credibility/Expectancy Questionnaire will be used to compare treatment expectancy between conditions. It measures how much the patient believes the therapy they are receiving will help to reduce their PNES. This will be completed initially after being randomized, after the first session, 4th session, 8th session and at the follow-up visits., 16-22 months|Session Summary Sheet (SSS), Assesses participant's therapeutic relationship, mastery of skill and involvement in therapy session. Completed by therapist at each intervention visit., 6-12 months|Illness Cognitions Scale, Participant will complete this 17-item scale measuring the degree to which they align with the sick role. Assessed at baseline visit and follow-up visits., 16-22 months|Other FND Symptoms Questionnaire, Assesses if participant has other functional symptoms (independent from their PNES), and evaluates the intensity and frequency of these symptoms. Completed by parent at Baseline and follow-up visits, 16-22 months|Dissociative Experiences Scale, Participant assesses this 28 item scale which assesses the severity of dissociation. Score ranges from 0 to 100% with a higher score indication greater dissociation. Completed at baseline and follow-ups., 16-22 months|Life Stress Inventory, Participant completes this 43 item scale which assesses susceptability to stress-induced health problems. Scores ranges from 0-430 with a higher score indicating greater susceptability to stress-induced health problems. Completed at baseline and follow-up visits., 16-22 months|Somatoform Dissociative Questionnaire, Participant completes this 20 item scale which evaluates the severity of somatoform manifestations of the dissociation of personality. Score ranges from 5-100 and a higher score indicates greater somatoform disorders due to personality dissociation. Completed at baseline and follow-up visits., 16-22 months